Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina
- PMID: 29188510
- DOI: 10.1007/978-1-4939-7522-8_9
Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina
Abstract
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein (Cas) is used by some bacteria and most archaea to protect against viral phage intrusion and has recently been adapted to allow for efficient editing of the mammalian genome. Whilst CRISPR/Cas-based technology has been used to modify genes in mammalian cells in vitro, delivery of CRISPR/Cas system into mammalian tissue and/or organs is more difficult and often requires additional vectors. With the use of adeno-associated virus (AAV) gene delivery system, active CRISPR/Cas enzyme can be maintained for an extended period of time and enable efficient editing of genome in the retina in vivo. Herein we outline the method to edit the genome in mouse retina using a dual AAV vector -mediated CRISPR/Cas9 system.
Keywords: AAV; CRISPR/Cas9; Gene delivery; Genome editing; Retina.
Similar articles
-
AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3470-6. doi: 10.1167/iovs.16-19316. Invest Ophthalmol Vis Sci. 2016. PMID: 27367513
-
Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.Methods Mol Biol. 2019;1950:123-139. doi: 10.1007/978-1-4939-9139-6_7. Methods Mol Biol. 2019. PMID: 30783971 Free PMC article.
-
Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.Circ Res. 2017 Oct 27;121(10):1168-1181. doi: 10.1161/CIRCRESAHA.116.310370. Epub 2017 Aug 29. Circ Res. 2017. PMID: 28851809
-
In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.Bioconjug Chem. 2017 Apr 19;28(4):880-884. doi: 10.1021/acs.bioconjchem.7b00057. Epub 2017 Mar 17. Bioconjug Chem. 2017. PMID: 28263568 Free PMC article. Review.
-
CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.Chem Rev. 2017 Aug 9;117(15):9874-9906. doi: 10.1021/acs.chemrev.6b00799. Epub 2017 Jun 22. Chem Rev. 2017. PMID: 28640612 Review.
Cited by
-
Comparison of CRISPR/Cas Endonucleases for in vivo Retinal Gene Editing.Front Cell Neurosci. 2020 Sep 10;14:570917. doi: 10.3389/fncel.2020.570917. eCollection 2020. Front Cell Neurosci. 2020. PMID: 33132845 Free PMC article.
-
Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.Sci Rep. 2022 Feb 14;12(1):2417. doi: 10.1038/s41598-022-06430-1. Sci Rep. 2022. PMID: 35165339 Free PMC article.
-
Lipopeptide-mediated Cas9 RNP delivery: A promising broad therapeutic strategy for safely removing deep-intronic variants in ABCA4.Mol Ther Nucleic Acids. 2024 Sep 26;35(4):102345. doi: 10.1016/j.omtn.2024.102345. eCollection 2024 Dec 10. Mol Ther Nucleic Acids. 2024. PMID: 39494150 Free PMC article.
-
Allele-Specific CRISPR-Cas9 Genome Editing of the Single-Base P23H Mutation for Rhodopsin-Associated Dominant Retinitis Pigmentosa.CRISPR J. 2018 Feb;1(1):55-64. doi: 10.1089/crispr.2017.0009. CRISPR J. 2018. PMID: 31021187 Free PMC article.
-
Gene-Based Therapeutics for Inherited Retinal Diseases.Front Genet. 2022 Jan 7;12:794805. doi: 10.3389/fgene.2021.794805. eCollection 2021. Front Genet. 2022. PMID: 35069693 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials